Stockscreener 앱 받기
3.8431
3.92%
-0.1569
전일 마감가:
$4.00
열려 있는:
$3.85
하루 거래량:
1,430
Relative Volume:
0.44
시가총액:
$192.17M
수익:
-
순이익/손실:
-
주가수익비율:
-5.2351
EPS:
-0.7341
순현금흐름:
-
1주 성능:
-6.27%
1개월 성능:
+1.13%
6개월 성능:
+10.75%
1년 성능:
-11.45%
1일 변동 폭
$3.8431
$3.8688
1주일 범위
$3.8431
$4.1419
52주 변동 폭
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.8431 | 200.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 재개 | H.C. Wainwright | Buy |
| 2021-12-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | 업그레이드 | Stifel | Hold → Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Underperform |
| 2020-05-13 | 다운그레이드 | Kepler | Buy → Reduce |
| 2020-05-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-05-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 재확인 | B. Riley FBR | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-04-24 | 개시 | SVB Leerink | Outperform |
| 2019-04-22 | 개시 | Barclays | Overweight |
모두보기
Genfit Adr 주식(GNFT)의 최신 뉴스
GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs See Mixed Results With Modest Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire
GENFIT: Ipsen and GENFIT enter into exclusive licensing - GlobeNewswire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr (GNFT) 재무 분석
Genfit Adr (GNFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.10%
자본화:
|
볼륨(24시간):